Latest Interferon type I Stories
Researchers at UT Southwestern Medical Center report the identification of a new cellular source for an important disease-fighting protein used in the body's earliest response to infection.
UCLA scientists have shown that temporarily blocking a protein critical to immune response actually helps the body clear itself of chronic infection.
Scientists at The Scripps Research Institute (TSRI) have made a counterintuitive finding that may lead to new ways to clear persistent infection that is the hallmark of such diseases as AIDS, hepatitis B and hepatitis C.
A metanalysis published in BioMed Central's open access journal BMC Medicine has confirmed that polymorphisms (SNP) in the gene coding for interleukin-28 (IL28B) influence natural hepatitis C viral (HCV) clearance and response to pegylated interferon-α plus ribavirin (PEG-IFN/RBV).
Whitehead Institute scientists have created a method that uses the enzyme sortase A to site-specifically modify proteins.
NES-ZIONA, Israel, April 1 /PRNewswire-FirstCall/ -- PROLOR Biotech, Inc.
A study published online on February 1 in the Journal of Experimental Medicine (www.jem.org) shows that antiviral proteins called type I interferons (IFNs) are needed to fend off infection with an exotic mosquito-borne virus called Chikungunya virus.